401 results about "SCC - Squamous cell carcinoma" patented technology

The invention discloses a Hsa-miR-145-5p kit and a use of a mature body analogy of the Hsa-miR-145-5p. The Hsa-miR-145-5p kit comprises the following quantitative detection components of a Hsa-miR-145-5p gene: a Hsa-miR-145-5p PCR primer, dNTP with the concentration of 10mM, an RNase inhibitor, a microRNA / cDNA reverse transcription primer, a buffer solution with the concentration of 5 times, M-MLV, a SYBRGreenPCRMasterMix mixing liquid with the concentration of 2 times, deionized water, a Hsa-miR-145-5pfluorescence in-situ hybridization probe and a FSCN1 immunohistochemical component, wherein the Hsa-miR-145-5pfluorescence in-situ hybridization probe is a base sequence complemented with a Hsa-miR-145-5p basic group and is modified by DNA skeleton and fluorophore cy3. The Hsa-miR-145-5p kit can be used for molecular targeting treatment medicine for Laryngeal carcinoma.

The invention discloses an esophageal squamous carcinoma radical postoperative patient prognosis prediction model construction method and device, and the method comprises the steps: obtaining clinical diagnosis and treatment data and follow-up visit survival data, carrying out multi-factor Cox regression analysis on patient characteristic variables, tumor pathology characteristic variables, treatment condition variables and test index variables according to follow-up visit survival data, carrying out variable screening by utilizing a step-by-step back algorithm and an Akaike information criterion, and carrying out variable screening on the screened candidate variables again to obtain modeling variables; and performing multi-factor Cox regression analysis on modeling variables and interaction items of every two modeling variables to construct a prognosis prediction model of a patient after the esophageal squamous carcinoma radical operation, wherein the prediction variables comprise age, gender, tumor primary position, T stage, lymph node detection number, tumor size, preoperative hemoglobin level and N stage treatment mode interaction items. According to the method, the prediction accuracy can be improved, the optimal benefit group of different treatment schemes is defined, and the prognosis evaluation precision of the esophageal squamous cell carcinoma is realized.

Disclosed is a method for preventing the development of head and neck squamous cell carcinoma (HNSCC) in a mammal who is at risk for developing such carcinoma comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor to the mammal. An example of such inhibitor is rapamycin.

The invention discloses application of a reagent for detecting and targeting a biomarker in oral squamous cell carcinoma. The biomarker is lncRNA LINC01679. The invention discloses application of theLINC01679 in preparation of a product for diagnosing the oral squamous cell carcinoma and the product for diagnosing the oral squamous cell carcinoma. Meanwhile, the invention discloses application ofthe LINC01679 in preparation of a pharmaceutical composition for treating the oral squamous cell carcinoma and the pharmaceutical composition for treating the oral squamous cell carcinoma.

The present invention provides a novel cancer marker that is useful in the diagnosis of urothelial cancer. The present invention uses ubiquilin 2 as a cancer marker for urothelial cancer (renal pelvis cancer, ureteral cancer, and bladder cancer). Detection of ubiquilin 2 in a urine sample allows easy and accurate diagnosis of a possibility of urothelial cancer. The present invention is also applicable to the diagnosis of squamous cancer (esophageal cancer, cervical cancer, etc.).